[Treatment of hypertension syndrome of pregnancy with ligustrazine].
75 patients with hypertension syndrome of pregnancy (HSP) were randomly designed to 2 groups: the control group treated with magnesium sulfate (20-25g/d) and the Ligustrazine (120-160mg/d) group. The results of Ligustrazine group compared with the control group were as follows: (1) Mean arterial pressure was significantly decreased (P less than 0.01). (2) Edema and proteinuria was lowered (P less than 0.05). (3) The condition of rheology was improved, especially, hematocrit was significantly decreased (P less than 0.001). (4) The positive rate of NST and Apgar's score were not different between the 2 groups. Clinical monitoring showed Ligustrazine without side effects in the group. Mechanisms of Ligustrazine in HSP were (1) dilating blood vessel; (2) improving kidney function; (3) improving microcirculatory and rheology.
Qian
X H
XH
Hubei Maternity and Child Health Hospital, Wuhan.
Huang
Y L
YL
Wu
S P
SP
D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D011719:Pyrazines / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D011719:Pyrazines; D014665:Vasodilator Agents; D008278:Magnesium Sulfate; C017953:tetramethylpyrazine